TrialJournal for immunotherapy of cancer2017

Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIM

Brendan Curti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.